Changing the logic of therapeutic angiogenesis for ischemic disease

Costanza Emanueli, Paolo Madeddu

Research output: Contribution to journalArticle (Academic Journal)peer-review

18 Citations (Scopus)


The worldwide epidemic of ischemic disease urgently requires innovative treatments. Recently, therapeutic angiogenesis has emerged as a noninvasive supply-side approach, aimed at promoting neovascularization in underperfused tissues through the local delivery of angiogenic growth factors. Successful preclinical studies paved the way for the first clinical trials, with single growth factors given as recombinant proteins or genes. However, clinical results have not matched the initial promises. Our opinion is that the logic of therapeutic angiogenesis needs profound revision. Here, we introduce the concept that pleiotropic agents can stimulate the healing of all the components of ischemic tissue. We also propose prophylactic interventions to delay vascular senescence. The optimization of therapeutic angiogenesis will open unprecedented opportunities for the care of life-threatening ischemic disease.

Translated title of the contributionChanging the logic of therapeutic angiogenesis for ischemic disease
Original languageEnglish
Pages (from-to)207 - 216
Number of pages10
JournalTrends in Molecular Medicine
Issue number5
Publication statusPublished - May 2005


  • Angiogenesis Inducing Agents
  • Animals
  • Clinical Trials as Topic
  • Humans
  • Myocardial Ischemia
  • Neovascularization, Pathologic
  • Neovascularization, Physiologic
  • Recombinant Proteins


Dive into the research topics of 'Changing the logic of therapeutic angiogenesis for ischemic disease'. Together they form a unique fingerprint.

Cite this